Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 23, 2017

DrugPatentWatch Database Preview

Ziprasidone hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for ziprasidone hydrochloride and what is the scope of ziprasidone hydrochloride freedom to operate?

Ziprasidone hydrochloride
is the generic ingredient in two branded drugs marketed by Aurobindo Pharma Ltd, Pfizer, Wockhardt Ltd, Lupin Pharms, Apotex Inc, Sandoz Inc, Dr Reddys Labs Inc, Macleods Pharms Ltd, Pfizer Inc, and Mylan Pharms Inc, and is included in ten NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Ziprasidone hydrochloride has one hundred and twenty-nine patent family members in fifty-three countries.

There are twenty-one drug master file entries for ziprasidone hydrochloride. Thirty-two suppliers are listed for this compound.

Summary for Generic Name: ziprasidone hydrochloride

Drug Master File Entries: see list21
Suppliers / Packagers: see list32
Bulk Api Vendors: see list162
Clinical Trials: see list1,057
Patent Applications: see list4,952
Therapeutic Class:Bipolar Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:ziprasidone hydrochloride at DailyMed

Pharmacology for Ingredient: ziprasidone hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
ziprasidone hydrochloride
CAPSULE;ORAL020825-004Feb 5, 2001ABRXYesNo6,245,766► Subscribe ► Subscribe
Macleods Pharms Ltd
ziprasidone hydrochloride
CAPSULE;ORAL204375-003Feb 17, 2017ABRXNoNo► Subscribe► Subscribe
Aurobindo Pharma Ltd
ziprasidone hydrochloride
CAPSULE;ORAL204117-003Dec 27, 2016ABRXNoNo► Subscribe► Subscribe
Lupin Pharms
ziprasidone hydrochloride
CAPSULE;ORAL077560-003Mar 2, 2012ABRXNoNo► Subscribe► Subscribe
Wockhardt Ltd
ziprasidone hydrochloride
CAPSULE;ORAL090348-002Sep 5, 2012ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus